OSCR Quantitative Stock Analysis

Validea's guru fundamental report highlights OSCAR HEALTH INC (OSCR) as highest-rated by its Kenneth Fisher-inspired Price/Sales Investor model, achieving a 60% score. While the mid-cap insurer passes on key valuation metrics such as Price/Sales and Free Cash Per Share, it notably fails on profitability and growth criteria, including long-term EPS growth rate and three-year average net profit margin. This mixed performance indicates OSCR does not meet the strategy's higher thresholds for strong investment interest, despite its favorable valuation metrics.

Analysis

Oscar Health Inc. (OSCR) presents a conflicting fundamental profile according to Validea's quantitative analysis based on the Kenneth Fisher Price/Sales Investor model. The mid-cap insurer achieved a score of 60%, which falls below the 80% threshold that typically signals notable investment interest from the strategy. The company shows strength on valuation and cash generation metrics, passing the model's criteria for Price/Sales Ratio and Free Cash Per Share. However, these positive factors are directly countered by significant weaknesses in core profitability and growth, as OSCR fails the tests for both Long-Term EPS Growth Rate and Three-Year Average Net Profit Margin. This specific dichotomy suggests that while the stock appears attractively priced relative to its revenue, its underlying financial performance regarding profitability and sustainable growth is weak, reflecting the mixed sentiment score of -0.1.

Key Decisions for Investors

• Investors should weigh the attractive Price/Sales valuation against the significant weakness in profitability, as highlighted by the failure on the three-year average net profit margin test.
• Given the explicit failure on long-term EPS growth criteria, the stock does not currently align with a growth-oriented investment thesis and may be more suitable for a watchlist.
• It is critical for potential investors to assess whether OSCR is a value trap, where the low valuation is justified by poor fundamentals, rather than a mispriced opportunity.
• Consider monitoring future earnings reports for a clear inflection in profitability and a sustainable path to EPS growth before committing capital, as the current 60% model score indicates caution.